CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.24B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.14: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.23%
Annual Rate
CNY 0.05Paid annual
Payout Ratio
4.7%Sustainable
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
8.37BCNY1.24B · vs all stocks (USD)
Trailing P/E
32.70xRevenue (TTM)
2.21BCNY328.16M · vs all stocks (USD)
Profit Margin
11.52%Beta
1.01xvs all stocks
52-Week Change
37.05%vs all stocks
Market Capitalization
8.37BCNY1.24B · vs all stocks (USD)
Enterprise Value
7.52BCNY1.12B · vs all stocks (USD)
Trailing P/E
32.70xPEG Ratio
0.0215xPrice to Sales (TTM)
3.79xPrice to Book (MRQ)
1.80xEnterprise to Revenue
3.40xEnterprise to EBITDA
15.97xGross Margin
32.00%Profit Margin
11.52%Operating Margin
23.79%Return on Assets (TTM)
2.71%Return on Equity (TTM)
5.64%Revenue (TTM)
2.21BCNY328.16M · vs all stocks (USD)
Revenue per Share (TTM)
5.57CNYUpdated Aug 20, 2026Quarterly Revenue Growth
62.30%Gross Profit (TTM)
492.34MCNY73.12M · vs all stocks (USD)
EBITDA (TTM)
402.95MCNY59.85M · vs all stocks (USD)
Net Income (TTM)
254.51MCNY37.80M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
1524.40%Operating Cash Flow (TTM)
-71.87MCNY-10.67M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-65.26MCNY-9.69M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0500CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.23%vs all stocks
Payout Ratio
4.68%Minority Interest (Equity)
-728.22KCNYFY2025 · Dec 31, 2025Revenue
1.94BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.58BCNYFY2025 · Dec 31, 2025Gross Profit
364.15MCNYFY2025 · Dec 31, 2025Operating Income
178.41MCNY26.50M · vs all stocks (USD)
Pre-tax Income
145.72MCNYFY2025 · Dec 31, 2025Income Tax Expense
28.09MCNYFY2025 · Dec 31, 2025Net Income
117.63MCNYFY2025 · Dec 31, 2025EBIT
159.50MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
402.95MCNYFY2025 · Dec 31, 2025Research & Development
83.90MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
54.55MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.56MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
13.79MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2999CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2999CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
396.98MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
396.98MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
117.63MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-499.67MCNYFY2025 · Dec 31, 2025Free Cash Flow
-653.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
387.59MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
117.63MCNYFY2025 · Dec 31, 2025Other Non-cash Items
18.23MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-579.11MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-56.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-153.98MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.47BCNYFY2025 · Dec 31, 2025Sale of Investments
5.39BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-240.63MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
504.55MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-307.91MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.07MCNYFY2025 · Dec 31, 2025Other Financing Charges
62.78MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
231.35MCNYFY2025 · Dec 31, 2025Shares Outstanding
400.01MSharesUpdated Aug 20, 2026Float Shares
159.03MSharesUpdated Aug 20, 2026% Held by Insiders
62.13%vs all stocks
% Held by Institutions
1.24%vs all stocks
Total Cash (MRQ)
1.59BCNY236.48M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.01CNYUpdated Aug 20, 2026Total Debt (MRQ)
601.17MCNY89.29M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1305xCurrent Ratio (MRQ)
2.88xBook Value per Share (MRQ)
11.61CNYUpdated Aug 20, 2026Total Assets
6.16BCNY915.57M · vs all stocks (USD)
Total Current Assets
3.30BCNYFY2025 · Dec 31, 2025Total Liabilities
1.71BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.87BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
464.57MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.24BCNYFY2025 · Dec 31, 2025Cash
387.40MCNYFY2025 · Dec 31, 2025Cash Equivalents
85.35MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
472.74MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.13BCNYFY2025 · Dec 31, 2025Accounts Receivable
449.53MCNYFY2025 · Dec 31, 2025Inventory
319.01MCNYFY2025 · Dec 31, 2025Accounts Payable
798.99MCNYFY2025 · Dec 31, 2025Short-term Debt
156.61MCNYFY2025 · Dec 31, 2025Other Current Liabilities
168.03MCNYFY2025 · Dec 31, 2025Long-term Debt
374.76MCNYFY2025 · Dec 31, 2025Common Stock (Book)
400.01MCNYFY2025 · Dec 31, 2025Retained Earnings
1.72BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.46BCNY662.22M · vs all stocks (USD)
Treasury Stock
47.15MCNYFY2025 · Dec 31, 202552-Week Low
13.97CNYUpdated Aug 20, 202652-Week High
35.58CNYUpdated Aug 20, 202652-Week Change
37.05%vs all stocks
Beta
1.01xvs all stocks
50-Day MA
23.20CNYUpdated Aug 20, 2026200-Day MA
23.23CNYUpdated Aug 20, 2026Avg 10-Day Volume
8.44MSharesUpdated Aug 20, 2026Avg 30-Day Volume
10.43MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.6400CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.62Receivables vs revenue divergence: 3.58
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 37,800,554.73Operating Cash Flow (USD, TTM): -10,673,469.407
Financial Health
Altman Z-Score 4.14: safe zoneNotable
Altman Z-Score: 4.14
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.24B, above the global median of $1.15BNotable
Market cap (USD): 1,243,430,577.96Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MannKind Corporation
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Corvus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sonoscape Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated